
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic Inc's pipeline, particularly the development of IMU-838, shows strong potential due to its favorable safety profile and improved treatment benefits for chronic inflammatory diseases, particularly relapsing-remitting multiple sclerosis (RMS). The Phase 2 studies have indicated that IMU-838 may offer comparable or superior efficacy compared to standard of care therapies while maintaining a low discontinuation rate, suggesting high tolerability among patients. Additionally, the dual mechanism of action encompassing both anti-inflammatory and neuroprotective properties positions IMU-838 uniquely within the competitive landscape, enhancing its prospects for successful market entry and acceptance.
Bears say
Immunic Inc has faced significant challenges with disappointing late-stage trial results, particularly with its candidates evobrutinib and tolebrutinib, which did not demonstrate superiority against the established treatment Aubagio, impacting their projected commercial viability. Additionally, the company reported a net loss of $25.6 million for the third quarter of 2025 and is under financial strain, with only $35 million in capital remaining to fund ongoing studies, raising concerns about securing further funding. The combination of mixed clinical outcomes, ongoing debates regarding the commercial opportunity of their products in a crowded market, and the need for additional capital contribute to a negative outlook for Immunic's stock.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares